Information Provided By:
Fly News Breaks for September 22, 2016
BLUE
Sep 22, 2016 | 08:06 EDT
Roth Capital analyst Mark Breidenbach assumed coverage of bluebird bio with a Buy rating and $87 price target based on a sum-of-parts, probability-adjusted NPV analysis of the company's pipeline. The analyst believes bluebird bio can no longer be considered a fledgling given the clinical success seen in its Lenti-D and Lentiglobin programs, both hatched from the company's versatile core lentiviral technology platform.